5 results match your criteria: "Tomsk National Research Center[Affiliation]"
Aim: Based on data from the Russian REGION-IM registry, to study the features of reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI) in real-life clinical practice.
Material And Methods: REGION-IM is a multicenter prospective observational study. The observational period is divided into 3 stages: during the stay in the hospital and at 6 and 12 months after inclusion in the registry.
Kardiologiia
August 2023
Research Institute of Cardiology, Tomsk National Research Center of the Russian Academy of Sciences.
Aim To study renal hemodynamics in patients with resistant arterial hypertension (RAH) in combination with type 2 diabetes mellitus (DM2) and to identify factors involved in the increase in intrarenal vascular resistance.Material and methods This study included 59 patients (25 men) with RAH in combination with DM2. Mean age of patients was 60.
View Article and Find Full Text PDFAim: To study interconnections between epicardial adipose tissue thickness (EATt), parameters of glucose metabolism/insulin, C-reactive protein (hsCRP), serum adipokines and severity of coronary artery disease (CAD) depending on the presence of diabetes mellitus type 2 (DM 2); to determine significant markers of CAD severity in patients with DM 2.
Materials And Methods: The study involved 106 patients with CAD (m/f 64/42, 60.96.
Bull Exp Biol Med
October 2018
Research Institute of Cardiology, Tomsk National Research Center, Russian Academy of Sciences, Tomsk, Russia.
We studied the effect of different concentrations of the allogeneic biotransplant on myocardial recovery. In Wistar rats, coronary artery was ligated and intramyocardial injection of 12 or 24 mg Alloplant biomaterial suspension was performed. Histological analysis was conducted on paraffin sections stained by Mallory.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
November 2017
Cancer Research Institute, Tomsk National Research Center, Russian Academy of Medical Sciences, Tomsk, Russia.
Background: The effect of the targeted therapy on cancer molecular markers remains currently unknown. The aim of the study was to investigate the expression and content of transcription, growth factors and components of the AKT/m-TOR signaling pathway in kidney cancer patients before and after targeted therapy with pazopanib. Methods: A total of 157 patients with renal cell carcinoma were enrolled into the study.
View Article and Find Full Text PDF